Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | MGLL | Q99685 | 2/20 | 0.39 |
| ▸ | PHGDH | O43175 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.32 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4550633 | 0.73 | CYP1A2 (0.52) | CYP1A2TDP1MGLLPHGDHHTT | |
| SCHEMBL20978539 | 0.67 | CYP1A2 (0.35) | CYP1A2TDP1MGLLPHGDHHTT | |
| SCHEMBL27463075 | 0.67 | CYP1A2 (0.57) | CYP1A2TDP1MGLLPHGDHHTT | |
| SCHEMBL8143096 | 0.65 | CYP1A2 (0.55) | CYP1A2TDP1MGLLPHGDHHTT | |
| SCHEMBL13895251 | 0.65 | MGLL (0.56) | CYP1A2TDP1MGLLPHGDHHTR1A | |
| SCHEMBL2743222 | 0.65 | CYP1A2 (0.55) | CYP1A2TDP1MGLLPHGDHHTT | |
| SCHEMBL33260 | 0.65 | CYP1A2 (1.00) | CYP1A2TDP1MGLLPHGDHHTT | |
| SCHEMBL13925516 | 0.65 | CYP1A2 (1.00) | CYP1A2TDP1MGLLPHGDHHTT | |
| Hydrochloric Acid SCHEMBL2338864 | 0.63 | CYP1A2 (0.94) | CYP1A2TDP1MGLLPHGDHHTT | |
| Hydrochloric Acid SCHEMBL22234282 | 0.63 | CYP1A2 (0.94) | CYP1A2TDP1MGLLPHGDHHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029636-A1 | Lck inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029636-A1 | Lck inhibitors | LCK, ZAP70, FYN | CYP1A2 3961/4885TDP1 451/4885MGLL 3667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.